Linkedin
Facebook
Twitter
Youtube

23 Feb Autolus

Posted at 18:44h in by

Christian Itin, Ph.D., Chairman and CEO
London, UK
(NASDAQ: AUTL)
Autolus is a biopharmaceutical company founded on advanced cell programming technology pioneered by Dr. Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T-cell product candidates. Autolus is committed to bringing life-changing treatments to cancer patients by reprogramming their own T-cells to combat the treatment of haematological malignancies and solid tumours. Autolus believe its programmed T-cell therapies have the potential to offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.
www.autolus.com



About the Event

The Cell & Gene Meeting on the Mediterranean is the leading conference bringing together the ATMP community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector, this program features expert-led panels, extensive one-on-one partnering capabilities, exclusive networking opportunities, and 80+ dedicated presentations by leading publicly traded and privately held companies in the space. Join ARM for Europe’s premier conference for advanced therapies.

Dates & Location

April 19-21, 2022
Barcelona, Spain

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions